GLP-1 Ozempic Semaglutide Tirzepatide Compounding Legal Updates

[madman]

To view this content we will need your consent to set third party cookies.
For more detailed information, see our cookies page.

Accept third party cookies

If your wellness clinic or med spa is offering (or planning to offer) GLP-1 medications like Ozempic, Wegovy, Mounjaro, or compounded semaglutide/tirzepatide, this legal update is a must-watch.

The regulatory landscape is changing fast, and staying compliant is critical. In this video, we break down everything you need to know from a legal and compliance perspective.




What You’ll Learn:

• Recent FDA Actions & Legal Developments

• Current Legal Status of Compounded GLP-1s

• Consent & Disclosure Requirements

• Scope of Practice: Who Can Prescribe & Administer

• Legal Risks of Off-Label Marketing & Delegation

• How to Stay Compliant in 2025 and Beyond




Have legal questions about offering GLP-1s in your practice? Visit us at LengeaLaw.com or send us a message to schedule a compliance consultation.

 

[madman]

https://www.cnbc.com/2025/04/01/eli-lilly-sues-strive-and-empower-over-compounded-tirzepatide.html

* Empower in a statement said restricting access to personalized alternatives to commercial drugs is not in the best interest of patients, and it’s “committed to offering these life-changing formulations.” Strive called Lilly’s lawsuit a classic example of Big Pharma overstepping legitimate regulations to prioritize its own interests and said it will vigorously defend its position.




Key Points

• Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding Zepbound and Mounjaro.

• Compounding of tirzepatide, the active ingredient in Lilly’s obesity drug Zepbound and diabetes drug Mounjaro, was largely supposed to stop last month.

• Lilly argues Strive and Empower are skirting the FDA’s ban on compounding.